Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY-NC 4.0Therapeutic Advances in Ophthalmology

Suprachoroidal hemorrhage and detachment in the non-laser photocoagulation posterior pole after intravitreal Anti-VEGF injection: A case report

  • Yikeng Huang1,2
  • Jisen Tang1
  • Chunyao Xie1
  • Xionggao Huang1
  1. 1Key Laboratory of Emergency and Trauma of Ministry of Education, Department of Ophthalmology, The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, Hainan Province, China
  2. 2Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Read full textDOICite

Abstract

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are widely used for diabetic macular edema (DME) and neovascular ocular diseases. Suprachoroidal hemorrhage and detachment (SCHD) in the posterior pole non-laser photocoagulation area is an extremely rare complication after anti-VEGF injection, with no standardized management. We report a 56-year-old male with a 20-year history of type 2 diabetes, bilateral proliferative diabetic retinopathy (DR), neovascular glaucoma (NVG), and prior pars plana vitrectomy who developed SCHD in the right eye after intravitreal Conbercept injection. He was treated with retrobulbar triamcinolone acetonide injection. During follow-up, SCHD resolved completely with significant improvement in best-corrected visual acuity and stable intraocular pressure. Pathogenesis may involve low intraocular pressure, anti-VEGF-related vascular effects, diabetic vascular fragility, and chronic high intraocular pressure injury. Retrobulbar triamcinolone acetonide injection may represent a promising treatment option for this complication, although further evidence is needed to establish its efficacy. Strict perioperative blood glucose and intraocular pressure control, standardized injection technique, and close postoperative monitoring may be beneficial for high-risk patients.

Related

  1. Comparison of Intravitreal Antivascular Endothelial Growth Factor Therapy in Treatment-Naïve vs Panretinal Photocoagulation–Treated Eyes With Proliferative Diabetic Retinopathy
    J. Fernando Arevalo, Andres F. Lasave, Lihteh Wu +15
    Journal of Vitreoretinal DiseasesPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC
  2. Intravitreal methotrexate as a prophylactic strategy for proliferative vitreoretinopathy in high-risk retinal detachment.
    Adrian Konstantin Luyken, Claudia Brockmann, Valentin Junge +3
    BMC ophthalmologyPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMCDOAJ
  3. When Degeneration Masquerades as Disease: Diagnosing Hypertrophic Olivary Degeneration on a Single Magnetic Resonance Imaging Examination in an Elderly Patient with Posterior Fossa Hemorrhage
    Atul Kumar, Pragya Chaturvedi, Shrea Gulati +1
    Annals of African MedicinePeer-reviewedCC BY-NC-SA 4.0Full textNeurologyPMC
  4. Detecting and Localizing Objects With Color-Contrast With a Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis
    Nick Barnes, Matthew A. Petoe, Maria Kolic +7
    Translational vision science & technologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial
    N. B. Pandey, A. C. Mirando, D. R. P. Almeida +6
    medRxivPreprintAll rights reservedFull textGeneral medicinemedRxiv

Cite

BibTeXRIS
BibTeX
@article{huang2026suprachoroidal,
  title = {{Suprachoroidal hemorrhage and detachment in the non-laser photocoagulation posterior pole after intravitreal Anti-VEGF injection: A case report}},
  author = {Yikeng Huang and Jisen Tang and Chunyao Xie and Xionggao Huang},
  journal = {Therapeutic Advances in Ophthalmology},
  year = {2026},
  month = sep,
  doi = {10.1177/25158414261491534},
  url = {https://doi.org/10.1177/25158414261491534},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Suprachoroidal hemorrhage and detachment in the non-laser photocoagulation posterior pole after intravitreal Anti-VEGF injection: A case report
AU  - Yikeng Huang
AU  - Jisen Tang
AU  - Chunyao Xie
AU  - Xionggao Huang
PY  - 2026
DA  - 2026/09/17
JO  - Therapeutic Advances in Ophthalmology
DO  - 10.1177/25158414261491534
UR  - https://doi.org/10.1177/25158414261491534
AB  - Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are widely used for diabetic macular edema (DME) and neovascular ocular diseases. Suprachoroidal hemorrhage and detachment (SCHD) in the posterior pole non-laser photocoagulation area is an extremely rare complication after anti-VEGF injection, with no standardized management. We report a 56-year-old male with a 20-year history of type 2 diabetes, bilateral proliferative diabetic retinopathy (DR), neovascular glaucoma (NVG), and prior pars plana vitrectomy who developed SCHD in the right eye after intravitreal Conbercept injection. He was treated with retrobulbar triamcinolone acetonide injection. During follow-up, SCHD resolved completely with significant improvement in best-corrected visual acuity and stable intraocular pressure. Pathogenesis may involve low intraocular pressure, anti-VEGF-related vascular effects, diabetic vascular fragility, and chronic high intraocular pressure injury. Retrobulbar triamcinolone acetonide injection may represent a promising treatment option for this complication, although further evidence is needed to establish its efficacy. Strict perioperative blood glucose and intraocular pressure control, standardized injection technique, and close postoperative monitoring may be beneficial for high-risk patients.
SN  - 2515-8414
ER  -